Hello myeloma Archives - The Myeloma Crowd

Stem Cell Transplant Still Improves Myeloma Patient Survival

With the advent of new drugs for the treatment of multiple myeloma, the role of stem cell transplant is frequently questioned. A recent study by researchers at UC Davis, published in the Journal of the National Cancer Institute, showed that autologous stem cell transplant improves survival for multiple myeloma patients. Interestingly, many patients who would qualify [...]

Read More

EHA: INSIGHT Update on Multiple Myeloma

The European Hematology Association is hosting its conference in Stockholm, Sweden this week, so watch for updates from on the Myeloma Crowd site.  One update is being presented from Takeda Oncology on their INSIGHT study to better understand how myeloma treatments are being administered in the clinic. There is no standard therapy in the management [...]

Read More

Full Show: Overcoming Proteasome Inhibitor Resistance, Muhamed Baljevic, MD, University of Nebraska

Thanks to our episode sponsor, Celgene Corporation Muhamed Baljevic, MD University of Nebraska Interview Date: May 28, 2018     Many patients' myeloma can become resistant to an important class of drugs use for myeloma care - proteasome inhibitors. Most patients (70%) will respond to these drugs as single therapies but some patients [...]

Read More

Added Venetoclax Improves Myeloma Patient Outcomes

According to an ongoing study, the addition of venetoclax (Venclexta) to the combination therapy of carfilzomib (Kyprolis) and dexamethasone (Kd) resulted in very high responses to relapsed/refractory myeloma patients. "Venetoclax plus Kd has shown promising preliminary efficacy," said lead investigator Luciano J. Costa, MD, PhD, associate professor of Medicine Blood and Marrow Transplantation and Cell [...]

Read More

ASCO: Daratumumab/Carfilzomib/Dex Combo Effective in Lenalidomide Relapsed or Refractory Multiple Myeloma

At the recent American Society of Clinical Oncology (ASCO) conference, Ajai Chari, MD of the the Mount Sinai School of Medicine presented results showing that daratumumab plus carfilzomib and dexamethasone (Dara-Kd) had promising effect and was generally well tolerated for patients who were refractory to lenalidomide.    Becoming refractory to lenalidomide can be common for [...]

Read More

SparkCures Founder Brian McMahon Named One of “40 Under 40 in Cancer”

Brian McMahon, CEO & Founder of SparkCures, was recently named as one of the nation’s top “40 under 40 in Cancer.” This award, which was presented during a cocktail reception on June 2, 2018 in Chicago, was created by The Lynx Group™ and McGivney Global Advisors, as a means of celebrating the contributions that individuals [...]

Read More

Myeloma Crowd Round Table Review: NYC – May 5, 2018

On May 5,  2018, a Myeloma Crowd Round Table meeting was held in New York, NY featuring six myeloma experts, including: Dr. Ruben Niesvizky, MD, New York Presbyterian Hospital-Cornell Medical Center Dr. Suzanne Lentzsch, Columbia University Medical Center Dr. Jens Hillengass, Roswell Cancer Institute, Buffalo, NY Dr. Markus Mapara, Columbia University Medical Center Dr. Divaya [...]

Read More

Legend Biotech and Janssen Partner on CAR T Cell Treatment for Multiple Myeloma

Janssen Pharmaceuticals (Johnson & Johnson) and Legend Biotech (GenScript Biotech Corporation) have announced the initiation of a clinical trial for patients with relapsed or refractory myeloma using Chimeric Antigen Receptor T cell (CAR-T) therapy. "This is a very exciting moment, as we celebrate the achievement of this critical milestone with our strategic partner Janssen," said [...]

Read More

Daratumumab with PD-1 Inhibitor Study Discontinued for Multiple Myeloma

Genmab announced that based on a planned review by the Data Monitoring Committee (DMC), two studies using daratumumab in combination with PD-1 inhibitors will be discontinued. The studies include daratumumab with atezolizumab for non-small cell lung cancer and daratumumab with JNJ-6372383 in multiple myeloma. The DMC determined that there was no observed benefit in the [...]

Read More

Clinical Trials and Compassionate Use in Multiple Myeloma

Every myeloma treatment available, even our first line therapies, began as a clinical trial. There are so many promising treatments currently in clinical trials, but the process can be long - often taking over a decade before a drug becomes approved and widely available. This process for new drugs is necessary to ensure our safety [...]

Read More

The Best Time to Take Dexamethasone… and Why

I am often asked, “When is the best time of day to take my dex….morning, mid-day, or bedtime”?  Let’s explore the answer from the aspect of normal human physiology. Cortisol is an adrenocorticoid produced each day by the adrenal gland.  It is essential to life, is a major factor in controlling our reaction to stress, [...]

Read More

Our Next Show: Overcoming Proteasome Inhibitor Resistance Using a New Drug with Muhamed Baljevic, MD, University of Nebraska, Monday, May 28 @ 2 pm Central

Monday, May 28, 2018 @ Noon Pacific, 1 pm Mountain, 2 pm Central, 3 pm Eastern Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer Many multiple myeloma patients can become resistant to an important class of myeloma drugs called proteasome inhibitors. Researchers found that expression of MUC20 could help [...]

Read More

Full Show: Introducing HealthTree for Multiple Myeloma Patients with Rafael Fonseca, MD, Mayo Clinic Scottsdale

Rafael Fonseca, MD Mayo Clinic Scottsdale Interview Date: May 18, 2018 Thanks to our episode sponsor, Takeda Oncology Summary Dr. Rafael Fonseca joins Myeloma Crowd Radio to share a new tool for myeloma patients called HealthTree. HealthTree can help myeloma patients find and understand personally relevant treatment options that can then be taken [...]

Read More

Patient Power: Cherie Rineker’s Post-CAR T-Cell Trial for Multiple Myeloma

Multiple myeloma patient Cherie Rineker gives Patient Power an inside look into her experience with CAR T-cell clinical trial. She shares the highs and lows of being in a clinical trial and provides insight into how clinical trials can provide tomorrow's medicine today. "I have done 13 different treatments for multiple myeloma. By the [...]

Read More

Small Study Results of Autologous Stem Cell Transplant and Kymriah to Treat Multiple Myeloma

Kymriah (marketed by Novartis), the first CAR-T treatment approved in the US (for Pediatric Acute Lymphocytic Leukemia) has now also been approved for the treatment of Diffuse Large B Cell Lymphoma (DLBCL). An article published in the most recent issue of the Journal of Clinical Investigation reports on the results of a small study [...]

Read More

Clinical Trial: BOSTON Trial, Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

The BOSTON trial is a phase 3 study comparing weekly oral selinexor + bortezomib + low-dose dexamethasone (SVd) versus bortezomib (twice weekly) + low-dose dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma. Patients whose myeloma progresses on the Vd arm may be eligible to “cross over” onto the SVd arm. Selinexor is the first in [...]

Read More

MCRT Review: Charlotte, NC – April 14, 2018

On April 14, 2018, a Myeloma Crowd Round Table meeting was held in Charlotte, NC featuring three myeloma experts, including: Dr. Adam Cohen, Abramson Cancer Center, University of Pennsylvania Dr. Peter Voorhees, Levine Cancer Institute, Charlotte, NC Dr. Saad Usmani, Levine Cancer Institute, Charlotte, NC Peter Voorhees, MD: Understanding Your Multiple Myeloma Genetics The [...]

Read More

Our Next Show: Introducing HealthTree with Rafael Fonseca, MD, Mayo Clinic Scottsdale, Friday, May 18 @ 2 pm Pacific

Friday, May 18, 2018 @ 2 pm Pacific, 3 pm Mountain, 4 pm Central, 5 pm Eastern Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer A new tool called HealthTree for multiple myeloma patients is coming in June! HealthTree is a tool to help myeloma patients improve their [...]

Read More

Donate Vitamin Bottles to TerraCycle, Raise Money for the Myeloma Crowd

TerraCycle is a company that reuses, upcycles, and recycles waste to allow it to cycle continually throughout our economy—which has numerous benefits.  Currently, TerraCycle is running a program of donating vitamin bottles for money. For each pound of vitamin bottles donated, $1 is donated to the Myeloma Crowd.  Multiple myeloma patient and support group leader, [...]

Read More

Understanding the Mutations that Cause Multiple Myeloma May Help Drive Personalized Treatment

 Affordable whole genome sequencing has helped researchers from the United Kingdom identify the mutations that drive the development of multiple myeloma and link that to potential opportunities to personalize treatment.   In a recent study by Richard Houlston, MD, PhD, Professor of Molecular and Population Genetics at The Institute of Cancer Research, London, new genes were identified [...]

Read More

FDA Orphan Status for Myeloma T Cell Therapy

The U.S. Food & Drug Adminstration (FDA) granted orphan status to a targeted immunotherapy drug for myeloma called galinpepimut (GPS) on May 9, 2018.  GPS is a vaccine that targets the WT1 antigen which, according to manufacturer SELLAS Life Sciences Group, “is one of the widely expressed cancer antigens” found a variety of cancer [...]

Read More

How Fast Your Multiple Myeloma Responds To Treatment May be Linked to Survival

A study recently done by the Mayo Clinic of Rochester, Minnesota evaluated the time it took patients to respond to their myeloma treatment and compared it to their overall survival. It hoped to give greater insight to prognostic factors and risk stratification of multiple myeloma patients.   Through patient observation and treatment therapy experimentation in over [...]

Read More

June 25, 2018: Swing for a Cure Pro-Am Golf Tournament in Detroit, MI

It is our pleasure to invite you to participate in Myeloma Crowd's 1st Annual Swing for a Cure Pro-Am Golf Tournament on Monday, June 25, 2018. This event is a combination of efforts between the Myeloma Crowd and Runyon Family Foundation to raise necessary funds for multiple myeloma research while playing golf at the beautiful Meadowbrook [...]

Read More

First Frontline Daratumumab Use Approved

Genmab A/S announced today that the US FDA approved the use of daratumumab (Darzalex) in combination with bortezomib, melphanal and prednisone (VMP) for newly diagnosed patients who are not eligible for a stem cell transplant. The license was submitted by Janssen Biotech, Inc.  in November 2017. Janssen has an exclusive worldwide license to develop, [...]

Read More

Staten Island Myeloma Support Group: September 11 Victims Fund Info

If you’re reading this, you know about myeloma. If you’re from the New York City area and spent a lot of time in Lower Manhattan on or after September 11, 2001 and were exposed—or know someone who was—to the dust and smells of the area for a prolonged time and were—or knows someone who [...]

Read More

Clinical Trials: What are Bispecific Antibodies?

Immunotherapy is a method of treating cancer that uses the body’s immune system to fight the cancer cells. A bispecific antibody is a type of immunotherapy being tested for use in the treatment of Multiple Myeloma. It differs from traditional monoclonal antibodies in that it is engineered to simultaneously target and bind to two different [...]

Read More

Blood Biopsies vs Bone Marrow Biopsies – The Good News For The Week …

… is a study that was published in the journal Nature Communications by a team from the Dana Farber Cancer Institute and the Broad Institute, a collaborative research effort between MIT and Harvard. This report summarizes the outcomes of a study that shows “that two ways to measure multiple myeloma DNA in blood samples [...]

Read More

MCRT Review: St Louis, Missouri – March 10, 2018

On March 10, 2018, a Myeloma Crowd Round Table meeting was held in St. Louis, Missouri featuring six myeloma experts, including: Dr. Gareth Morgan, University of Arkansas Myeloma Institute, Little Rock, AR Dr. Brian Van Ness, University of Minnesota, Minneapolis, MN Dr. Jens Hillengass, Roswell Park Cancer Institute, Buffalo, NY Dr. Ravi Vij, Washington University, [...]

Read More

Antibody-Drug Conjugates and Multiple Myeloma

The short title for this post may, hopefully, pack quite a punch against multiple myeloma. ADCs, shorthand for antibody-drug conjugates, are an important class of biopharmaceuticals that work very differently compared to chemotherapy. Whereas chemo attacks both malignant and healthy cells, ADCs are intended to only kill the cancerous cells and spare the surrounding [...]

Read More

First Results Published of P-BCMA-101 CAR-T in Relapsed/Refractory Multiple Myeloma

Poseida Therapeutics presented data from the Phase I (lowest dose cohort) of their novel CAR-T product, P-BCMA-101, at last week’s annual meeting of the American Association for Cancer Research (AACR). The presentation focused on the results achieved in the first step of their dose escalation study (NCT03288493)  in patients with relapsed/refractory multiple myeloma. The [...]

Read More

Allergic to Your Myeloma Meds? How One Mayo Clinic Patient Overcame a Pomalidomide Allergy

Originally seen on the Mayo Clinic website. Bob Christmas had gone through a bone marrow transplant and several medication regimens to keep multiple myeloma in check. But the disease kept coming back. Then he learned he was allergic to the very medication that offered the best chance to control his cancer. Mayo Clinic pharmacists, allergists [...]

Read More

A Way to Improve the Impact of Daratumumab

Daratumomab (Darzalex) and its use in combination with other drugs is becoming a new standard of care in the treatment of multiple myeloma. 'DARZALEX® is a monoclonal antibody that works in several ways. One way this monoclonal antibody works is by attaching itself to multiple myeloma cells in your body and directly killing them, [...]

Read More

Full Show: First Risk-Adapted Therapy Trial for Newly Diagnosed Patients (the MASTER trial) with Luciano Costa, MD, PhD, UAB

Luciano Costa, MD, PhD University of Alabama at Birmingham Interview Date: April 16, 2018 Thanks to our episode sponsor, Celgene Corporation. Summary Myeloma researchers are learning that the deeper our remissions, the better our outcomes (overall). Dr. Costa joins Myeloma Crowd Radio to share a key study for newly diagnosed multiple myeloma [...]

Read More

Understanding Multiple Myeloma—A Book Review

Understanding Multiple Myeloma is a comprehensive book that can be a guide to anyone with multiple myeloma. Written by Dr. Cristina Gasparetto, Associate Professor of Medicine and Director of Multiple Myeloma Program at Duke University Medical Center and Dharshan Sivaraj of the Duke University Division of Cellular Therapy & Hematologic Malignancies, the book aims to [...]

Read More

MCRT: Baltimore, Maryland–March 28, 2018

On March 28, 2018, a Myeloma Crowd Round Table meeting was held in Baltimore, Maryland with a group of four regional myeloma experts, including: Dr. Ashraf Badros, University of Maryland Greenebaum Cancer Center Dr. Ivan Borrello, The Johns Hopkins School of Medicine Dr. William Matsui, The Johns Hopkins School of Medicine Dr. David Vesole, Georgetown [...]

Read More

Patient Power: How Can Myeloma Patients Combat Neuropathy?

  How can myeloma patients combat the pain and numbness caused by neuropathy? Are there alternative treatment regimens? Patient Power meets with a panel of experts, including Dr. Frits van Rhee, Dr. Guido Tricot, Dr. Faith Davies and Dr. Gareth Morgan,  discussing ways  to work with your medical team to help reduce the intensity of [...]

Read More

Clinical Trial: BCMA CAR-T Plus LY3039478 Inhibitor in Multiple Myeloma

The use of CAR-T cell therapy is expanding in the treatment of multiple myeloma. Currently, several centers are producing their own CAR-T cell products. This clinical trial is open at the Fred Hutchinson Cancer Center. This phase I trial determines the side effects and best dose of B-cell maturation antigen (BCMA)-chimeric antigen receptor (CAR) [...]

Read More

Annual Survival Rate Statistics Update—Multiple Myeloma Rate Unchanged

New observational data from the United States National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) shows that the survival rate for multiple myeloma has stabilized with little change within the past year. This is comparative to the sizable increases of survival rates within the last two years. Five-Year Relative Survival of U.S. Multiple [...]

Read More

Caregiving For A Loved One—What You Should Know

When a loved one is diagnosed with myeloma (or really any chronic disease), the feeling of shock is overwhelming. There are many different thoughts that start to run through one’s mind. Most frequently, one wonders “How am I supposed to care for my loved one?” Upon embarking on this difficult and unfortunate journey, it is [...]

Read More

Stand Up To Cancer Takes New Approach to Multiple Myeloma, Focusing on Precursor Conditions

Originally seen on Markets Insider. Stand Up To Cancer announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma, an incurable blood cancer of plasma cells, through early detection of precursor conditions before they turn into full-blown disease. The SU2C Multiple Myeloma Dream Team [...]

Read More

40 Genes that Can be Disrupted in Early Stages of Multiple Myeloma

The most recent issue of the journal Leukemia summarizes the results of a study completed by researchers at the Institute of Cancer Research in London. The research team mapped and examined whole genome sequencing data from 765 multiple myeloma patients. The authors start the article with a forceful statement : “Multiple myeloma (MM) is a [...]

Read More

Selinexor Gets FDA Fast-Track Status for Penta-Refractory Myeloma Patients

Karyopharm Therapeutics recently announced that their oral drug selinexor (Selective Inhibitor of Nuclear Export) is obtaining FDA fast-track status for myeloma patients who have received three prior lines of therapy. Those three lines must have included five different drug classes: Chemotherapy like melphalan or cyclophosphamide A proteasome inhibitor like bortezomib or carfilzomib An immunomodulator [...]

Read More

Making Myeloma Drugs More Targeted and Effective Using Actinium Warhead Enabling (AWE) Technology

At the recent American Association for Cancer Research (AACR) annual meeting in Chicago, Actinium Pharmaceuticals showed data on a new technology that helps more specifically deliver myeloma drugs to tumor cells using a radioactive isotope.The company teamed up with Astellas Pharma, Inc. who tested regular daratumumab vs. daratumumab combined with a radioisotope Actinium-225. At the [...]

Read More

Myeloma 101: FISH Testing in Myeloma

FISH testing (fluorescence in situ hybridization) is a way of testing myeloma genetics in individual patients. It uses special fluorescent dyes that only attach to specific parts of chromosomes. FISH can find most chromosome changes (such as deletions or translocations) that can be seen under a microscope in standard cytogenetic tests, as well as [...]

Read More

Myeloma 101: NCCN Guidelines for Multiple Myeloma

NCCN is a ‘must know’ acronym. It stands for the National Comprehensive Cancer Network, a non-profit alliance of 27 leading cancer centers‘devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at [...]

Read More

Myeloma Crowd Cycling Club – Join Us Today!

We'd like to invite you to join the new Myeloma Crowd Cycling Club! Avid cyclist and myeloma patient, Richard Hite, and the Myeloma Crowd team created this club in an effort to encourage patients and cyclists everywhere to "ride for a cure."  The Myeloma Crowd Cycling team will be participating in multiple cycling events throughout [...]

Read More

Get Started Today.

Find a Clinical Trial that's Right for You

Thanks to our site sponsors: